Vivos Therapeutics Net Cash Flow 2020-2025 | VVOS

Vivos Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Vivos Therapeutics Net Cash Flow 2020-2025 | VVOS

Vivos Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.3B
Zoetis (ZTS)$67.6B
Takeda Pharmaceutical (TAK)$47B
Daiichi Sankyo, - (DSNKY)$46.1B
BeOne Medicines - (ONC)$33.7B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$20B
Merck (MKKGY)$16.8B
Shionogi (SGIOY)$15.5B
United Therapeutics (UTHR)$14B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.6B
Madrigal Pharmaceuticals (MDGL)$8.3B
Corcept Therapeutics (CORT)$7.7B
Grifols, S.A (GRFS)$7.3B
Ionis Pharmaceuticals (IONS)$6.9B
Stevanato Group S.p.A (STVN)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
NewAmsterdam Pharma (NAMS)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B